CLINICAL TRIALS PROFILE FOR IRESSA
✉ Email this page to a colleague
All Clinical Trials for Iressa
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00005806 ↗ | Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer | Completed | National Cancer Institute (NCI) | Phase 1 | 1999-09-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy in treating patients who have advanced non-small cell lung cancer. |
| NCT00005806 ↗ | Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer | Completed | Memorial Sloan Kettering Cancer Center | Phase 1 | 1999-09-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy in treating patients who have advanced non-small cell lung cancer. |
| NCT00006048 ↗ | ZD 1839 Plus Combination Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer | Unknown status | AstraZeneca | Phase 3 | 2000-05-01 | RATIONALE: Some tumors need growth factors produced by the body's white blood cells to keep growing. ZD 1839 may interfere with the growth factor and stop the tumor from growing. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether chemotherapy is more effective with or without ZD 1839 for non-small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without ZD 1839 in treating patients who have stage IIIB or stage IV non-small cell lung cancer. |
| NCT00006049 ↗ | ZD 1839 Plus Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer | Unknown status | AstraZeneca | Phase 3 | 2000-05-01 | RATIONALE: Some tumors need growth factors produced by the body's white blood cells to keep growing. ZD 1839 may interfere with the growth factor and stop the tumor from growing. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether combination chemotherapy is more effective with or without ZD 1839 for non-small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without ZD 1839 in treating patients who have stage III or stage IV non-small cell lung cancer. |
| NCT00012337 ↗ | ZD 1839 in Treating Patients With Metastatic Kidney Cancer | Completed | National Cancer Institute (NCI) | Phase 2 | 2001-01-01 | RATIONALE: Some tumors need growth factors produced by the body's white blood cells to keep growing. Drugs such as ZD 1839 may interfere with the growth factors and cause tumor cells to die. PURPOSE: Phase II trial to study the effectiveness of ZD 1839 in treating patients who have metastatic kidney cancer. |
| NCT00012337 ↗ | ZD 1839 in Treating Patients With Metastatic Kidney Cancer | Completed | Memorial Sloan Kettering Cancer Center | Phase 2 | 2001-01-01 | RATIONALE: Some tumors need growth factors produced by the body's white blood cells to keep growing. Drugs such as ZD 1839 may interfere with the growth factors and cause tumor cells to die. PURPOSE: Phase II trial to study the effectiveness of ZD 1839 in treating patients who have metastatic kidney cancer. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Iressa
Condition Name
Clinical Trial Locations for Iressa
Trials by Country
Clinical Trial Progress for Iressa
Clinical Trial Phase
Clinical Trial Sponsors for Iressa
Sponsor Name
